FibroGen is a pioneering brand that operates at the forefront of groundbreaking science and patient care. They are dedicated to identifying and developing innovative drugs that have the potential to become first-in-class medicines for the treatment of chronic and life-threatening conditions such as anemia, Duchenne muscular dystrophy (DMD), and locally advanced pancreatic cancer (LAPC). The brand's product candidates leverage the body's natural pathways, allowing for the exploration of their potential across multiple diseases.

Their most advanced therapeutic, roxadustat, is an oral small molecule inhibitor that induces the body's natural process of producing red blood cells, increasing iron absorption and transport. Roxadustat is approved for the treatment of anemia in chronic kidney disease (CKD) patients in various countries and is currently under review for other indications. Additionally, FibroGen is developing pamrevlumab, a potential first-in-class antibody that inhibits the activity of connective tissue growth factor (CTGF).

It is currently being evaluated for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and Duchenne muscular dystrophy (DMD). Pamrevlumab has shown promising results and has been granted Orphan Drug Designation (ODD) and Fast Track designation by the U. S.

Food and Drug Administration. FibroGen's commitment to advancing research and providing innovative therapies demonstrates their dedication to improving patient outcomes and quality of life